Stępień-Kłos Wioletta, Michalska-Kasiczak Marta, Płoszka Katarzyna, Stuss Michał, Sewerynek Ewa
Department of Endocrine Disorders and Bone Metabolism, Chair of Endocrinology, Medical University of Lodz, Lodz, Poland.
Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland.
Endokrynol Pol. 2025;76(1):74-81. doi: 10.5603/ep.102879.
The authors of the latest recommendations state that osteoporosis diagnosis should not rely solely on densitometric (DXA) criteria. Fracture risk assessment is crucial for determining diagnosis and intervention thresholds. Comprehensive assessment of fracture risk requires consideration of bone mineral density (BMD) results, use of risk calculators like Fracture Risk Assessment Tool (FRAXTM), and analysis of clinical and lifestyle factors. Experts highlight the need to identify patients at very high fracture risk to justify starting anabolic therapy. This retrospective study assessed fracture risk in newly diagnosed osteoporosis patients, identifying those at high and very high risk.
The study included 159 postmenopausal women with newly diagnosed osteoporosis, identified by a T-score of ≤ -2.5 standard deviations (SD) from DXA scans of the femoral neck and/or lumbar spine. Demographic data and laboratory tests were collected, and the 10-year fracture risk for major osteoporotic fractures (FRAX MOF) and hip fractures (FRAX HF) was calculated using the FRAX-PL calculator, which included femoral neck BMD. Each patient was then classified into a risk group based on modified fracture risk assessment criteria.
The study found that the most common risk factor for osteoporosis was a previous fracture (56.6%). Other common risk factors included smoking (21.38%), parental hip fracture (13.21%), and glucocorticoid use (10.70%). The FRAX calculator showed that 47.80% of patients were at very high risk for HF and 23.90% for MOF. A high HF risk was present in 10.06% of patients, and high MOF risk in 34.59%, whereas a medium and low MOF risk concerned 25.79% and 15.72% of the subjects, respectively. With expanded criteria, 72.33% of patients were classified at very high risk, compared to 23.90% for MOF and 47.80% for HF based solely on FRAX. Most patients met the T-score ≤ -3.0 SD criterion (52.20%) and FRAX > 15% for MOF or FRAX > 4.5% for HF (52.20%). Women aged 65-70 and 70-75 years are at the highest risk and qualify for anabolic therapy.
Our study highlights the importance of stratifying patients by fracture risk, showing that more individuals are identified at very high risk when using the expanded assessment criteria from the latest Polish guidelines.
最新建议的作者指出,骨质疏松症的诊断不应仅依赖于骨密度测定(DXA)标准。骨折风险评估对于确定诊断和干预阈值至关重要。骨折风险的综合评估需要考虑骨矿物质密度(BMD)结果、使用骨折风险评估工具(Fracture Risk Assessment Tool,FRAXTM)等风险计算器以及分析临床和生活方式因素。专家强调,有必要识别骨折风险极高的患者,以便为开始使用促合成代谢疗法提供依据。这项回顾性研究评估了新诊断的骨质疏松症患者的骨折风险,识别出高风险和极高风险患者。
该研究纳入了159名新诊断为骨质疏松症的绝经后女性,通过股骨颈和/或腰椎的DXA扫描T值≤ -2.5标准差(SD)确定。收集了人口统计学数据和实验室检查结果,并使用包含股骨颈骨密度的FRAX-PL计算器计算主要骨质疏松性骨折(FRAX MOF)和髋部骨折(FRAX HF)的10年骨折风险。然后根据改良的骨折风险评估标准将每位患者分为一个风险组。
研究发现,骨质疏松症最常见的风险因素是既往骨折(56.6%)。其他常见风险因素包括吸烟(21.38%)、父母髋部骨折(13.21%)和使用糖皮质激素(10.70%)。FRAX计算器显示,47.80%的患者髋部骨折风险极高,23.90%的患者主要骨质疏松性骨折风险极高。10.06%的患者髋部骨折风险高,34.59%的患者主要骨质疏松性骨折风险高,而中等和低主要骨质疏松性骨折风险分别涉及25.79%和15.72%的受试者。采用扩展标准后,72.33%的患者被归类为极高风险,而仅基于FRAX,主要骨质疏松性骨折风险为23.90%,髋部骨折风险为47.80%。大多数患者符合T值≤ -3.0 SD标准(52.20%)以及主要骨质疏松性骨折FRAX > 15%或髋部骨折FRAX > 4.5%(52.20%)。65 - 70岁和70 - 75岁的女性风险最高,符合促合成代谢疗法的条件。
我们的研究强调了按骨折风险对患者进行分层的重要性,表明使用最新波兰指南中的扩展评估标准时,会识别出更多骨折风险极高的个体。